Navigation Links
Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor

LONDON, April 4, 2007--Treatment data from Synovate Healthcare’s European Oncology Monitor reveals that over 10,000 breast cancer patients in the UK could become eligible for a breast cancer treatment showing lower death rates in patients. The treatment was the subject of a recent study detailed in the online edition of The Lancet (12 February 2007). Lower mortality rates were shown in patients who had switched to the aromotase inhibitor, Aromasin (exemestane), after 2-3 years of the current standard hormone drug therapy, tamoxifen. Aromasin was recently approved by the National Institute for Clinical Excellence (NICE).

Patients who could be eligible in this new indication were defined as newly diagnosed women in early stage disease who test positive for markers indicating hormone therapy as a treatment option, as well as those who have been on tamoxifen for 3 years or less. According to Synovate Healthcare’s data, 80% of drug-treated patients diagnosed in early stages are hormone responsive. Types of hormone therapies include tamoxifen and three aromatase inhibitors recently approved by the NICE. About 13% of newly diagnosed early stage breast cancer patients receive tamoxifen therapy in the UK annually.

Cancer Research UK and Globocan statistics from the World Health Organisation suggest that over 40,000 cases of breast cancer are diagnosed in the UK each year. Synovate Healthcare data shows that over 23,000 newly diagnosed patients are treated with drug therapies. Using data on the number of newly diagnosed women in early stage disease, together with the number of existing patients on tamoxifen, Synovate Healthcare estimates that over 10,000 breast cancer patients in the UK could become eligible for this new treatment within the next year.

Leah Krukowski, Head of Synovate Healthcare’s European Oncology Monitor, commented, “It is encouraging to see how many peoples& rsquo; lives could be positively affected by this treatment.” The European Oncology Monitor is an anonymous patient diary study run continuously in the UK, France, Germany, Italy and Spain, updated on a monthly basis.

Please note sample sizes: 2005 Q4 to 2006 Q3 = 1496 UK patients

- Ends -

About the Synovate Healthcare Global Oncology Monitor

The Synovate Healthcare Global Oncology Monitor covers 10 countries globally (UK, France, Italy, Germany, Spain, US, Japan, Australia, China and Korea) and is subscribed to by 50 companies worldwide. It is the largest and most frequently updated international drug-treated oncology patient sample.

About Synovate Healthcare

Synovate Healthcare is the global specialist healthcare market research arm of Synovate, dedicated to delivering marketing insights to the pharmaceutical and healthcare industries. Synovate Healthcare employs some 500 healthcare market research professionals across Europe, US and Asia Pacific and offers global fieldwork capabilities. For further details, visit www.synovate.com/healthcare.

About Synovate

Synovate is the market research arm of Aegis Group plc that generates consumer insights which drive competitive marketing solutions. The network provides clients with cohesive global support and a comprehensive suite of research solutions. Synovate employs over 5,000 staff in more than 100 offices across 50+ countries. More information on Synovate can be found at www.synovate.com.

www.synovate.com/healthcare

Telephone: +44 (0) 20 8246 6200
Fax: +44 (0) 20 8246 6300

Leah Krukowski
leah.krukowski@synovate.com
Tel: +44 208 246 6200


'"/>




Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
4. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
5. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
6. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
7. Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds
8. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
9. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
10. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery and ... revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, with ... revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional back ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
Breaking Medicine News(10 mins):